Autoantibody Signature for the Serologic Detection of Ovarian Cancer
Anderson, Karen S.
MetadataShow full item record
CitationAnderson, Karen S., Daniel W. Cramer, Sahar Sibani, Garrick Wallstrom, Jessica Wong, Jin Park, Ji Qiu, Allison Vitonis, and Joshua LaBaer. 2014. “Autoantibody Signature for the Serologic Detection of Ovarian Cancer.” Journal of Proteome Research 14 (1): 578-586. doi:10.1021/pr500908n. http://dx.doi.org/10.1021/pr500908n.
AbstractSera from patients with ovarian cancer contain autoantibodies (AAb) to tumor-derived proteins that are potential biomarkers for early detection. To detect AAb, we probed high-density programmable protein microarrays (NAPPA) expressing 5177 candidate tumor antigens with sera from patients with serous ovarian cancer (n = 34 cases/30 controls) and measured bound IgG. Of these, 741 antigens were selected and probed with an independent set of ovarian cancer sera (n = 60 cases/60 controls). Twelve potential autoantigens were identified with sensitivities ranging from 13 to 22% at >93% specificity. These were retested using a Luminex bead array using 60 cases and 60 controls, with sensitivities ranging from 0 to 31.7% at 95% specificity. Three AAb (p53, PTPRA, and PTGFR) had area under the curve (AUC) levels >60% (p < 0.01), with the partial AUC (SPAUC) over 5 times greater than for a nondiscriminating test (p < 0.01). Using a panel of the top three AAb (p53, PTPRA, and PTGFR), if at least two AAb were positive, then the sensitivity was 23.3% at 98.3% specificity. AAb to at least one of these top three antigens were also detected in 7/20 sera (35%) of patients with low CA 125 levels and 0/15 controls. AAb to p53, PTPRA, and PTGFR are potential biomarkers for the early detection of ovarian cancer.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:23845364